reBom failed current good manufacturing practice for OTC drugs, including inadequate stability and component testing.
What happened
FDA found the violations by reviewing records reBom submitted after FDA’s November 9, 2022, and February 26, 2024, requests, not from an inspection. The records did not show an adequate stability program; for example, dermaFit Athlete Muscle Maintenance Cream had only three months of stability data for one batch despite a two-year expiration date, and chemical and microbiological testing was missing. FDA also said reBom did not show adequate identity and purity testing of incoming components, including a limit test for diethylene glycol and ethylene glycol on all glycerin lots, and finished-product certificates of analysis lacked assay and microbiological testing.
What FDA found
The company did not establish and follow an adequate written stability testing program; dermaFit had only three months of data for a product labeled with a two-year expiration.
21 CFR 211.166(a)The company did not show it tested each incoming component for identity and conformity with purity, strength, and quality specifications.
21 CFR 211.84(d)(1) and 211.84(d)(2)The company did not include a limit test for diethylene glycol (DEG) and ethylene glycol (EG) on all lots of glycerin before use.
21 CFR 211.84(d)(1) and 211.84(d)(2)The company did not show adequate finished-product testing; certificates of analysis for dermaFit lacked an assay for active ingredient content and microbiological testing.
What FDA wants
FDA tells reBom to correct the violations promptly and respond in writing within 15 working days with what it has done and how it will prevent recurrence. If it cannot finish corrective actions in that time, it must state why and give a completion schedule.
Who should pay attention
- brands that buy OTC drug products from this contract manufacturer
- companies sourcing glycerin or other high-risk drug components
- U.S. distributors and importers of reBom drug products
This is a summary. Read the original letter on fda.gov.